| Induction chemotherapy |
|
| received one cycle of induction chemotherapy |
23(100) |
| Concurrent chemoradiation |
|
| Radiotherapy |
|
| received total dose of radiotherapy |
23(100) |
| radiotherapy interruptions |
2(8.7) |
| radiotherapy discontinuation |
0(0) |
| Chemotherapy |
|
| received one cycle of concurrent chemotherapy |
19(82.6) |
| did not receive concurrent chemotherapy |
4(17.4) |
| Nimotuzumab |
|
| received eigtht weeks of nimotuzumab |
19(82.6) |
| did not receive eigtht weeks of nimotuzumab |
4(17.4) |
| received 7 weeks of nimotuzumab |
1(4.3) |
| received 6 weeks of nimotuzumab |
2(8.7) |
| received 1 weeks of nimotuzumab |
1(4.3) |
| Adjuvant chemotherapy |
|
| not scheduled to receive adjuvant chemotherapy |
3(13.0) |
| scheduled to receive adjuvant chemotherapy |
20(87.0) |
| received 4 cycles of adjuvant chemotherapy |
18(78.4) |
| received 3 cycles of adjuvant chemotherapy |
1(4.3) |
| received 2 cycles of adjuvant chemotherapy |
1(4.3) |
